Literature DB >> 28913877

Minimal important difference of target lobar volume reduction after endobronchial valve treatment for emphysema.

Jorrit B A Welling1, Jorine E Hartman1, Eva M van Rikxoort2, Nick H T Ten Hacken1, Huib A M Kerstjens1, Karin Klooster1, Dirk-Jan Slebos1.   

Abstract

BACKGROUND AND
OBJECTIVE: Target lobar volume reduction (TLVR) is an important efficacy outcome measure for bronchoscopic lung volume reduction (BLVR) treatment using one-way endobronchial valves (EBV) in patients with severe emphysema. The commonly used cut-off value for TLVR that expresses a perceivable clinical benefit is -350 mL. However, a scientifically determined minimal important difference (MID) for TLVR never has been published. The objective of the present study was to determine the MID for TLVR on HRCT in patients who were treated with EBV.
METHODS: A total of 318 patients with severe emphysema from two BLVR trials were analysed. Anchor-based methods were used to define the TLVR MID at 6 months follow-up. Forced expiratory volume in 1 s (FEV1 ), residual volume (RV) and St. George's Respiratory Questionnaire (SGRQ) were used as anchors.
RESULTS: The calculated TLVR MID with each anchor was: FEV1 -587 mL, RV -534 mL and SGRQ -560 mL. The combined MID (average of the three anchor-based MIDs) was -563 mL.
CONCLUSION: Using the anchor-based method, we established a TLVR MID of -563 mL in patients with severe emphysema at 6 months follow-up after EBV treatment. This value can be useful for both interpreting the results from trials and clinical practice, as well as for designing future studies on lung volume reduction.
© 2017 Asian Pacific Society of Respirology.

Entities:  

Keywords:  chronic obstructive pulmonary disease; emphysema; lung volume reduction; minimal important difference; valves

Mesh:

Year:  2017        PMID: 28913877     DOI: 10.1111/resp.13178

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  10 in total

Review 1.  Valve therapy in patients with emphysematous type of chronic obstructive pulmonary disease (COPD): from randomized trials to patient selection in clinical practice.

Authors:  Arschang Valipour
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

Review 2.  Bronchoscopic Lung Volume Reduction: A 2018 Review and Update.

Authors:  Aşkın Gülşen
Journal:  Turk Thorac J       Date:  2018-07-01

3.  A New Oxygen Uptake Measurement Supporting Target Selection for Endobronchial Valve Treatment.

Authors:  Jorrit B A Welling; Karin Klooster; Jean-Paul Charbonnier; Eva M Van Rikxoort; Clemens R M Barends; Huib A M Kerstjens; Nick H T Ten Hacken; Jorine E Hartman; Dirk-Jan Slebos
Journal:  Respiration       Date:  2019-09-03       Impact factor: 3.580

4.  First in Human Experience of the Performance of the New 5.5-LP Size Zephyr Endobronchial Valve.

Authors:  Karin Klooster; Marlies van Dijk; T David Koster; Dirk-Jan Slebos
Journal:  Respiration       Date:  2019-11-26       Impact factor: 3.580

5.  The REACH Trial: A Randomized Controlled Trial Assessing the Safety and Effectiveness of the Spiration® Valve System in the Treatment of Severe Emphysema.

Authors:  Shiyue Li; Guangfa Wang; Changhui Wang; Xinglin Gao; Faguang Jin; Huaping Yang; Baohui Han; Rui Zhou; Chengshui Chen; Liangan Chen; Chunxue Bai; Huahao Shen; Felix J F Herth; Nanshan Zhong
Journal:  Respiration       Date:  2018-12-14       Impact factor: 3.580

6.  Clinical outcomes and quantitative CT analysis after bronchoscopic lung volume reduction using valves for advanced emphysema.

Authors:  Fangfang Guo; Junfang Huang; Yan Hu; Jianxing Qiu; Hong Zhang; Wei Zhang; Yuan Cheng; Jiping Liao; Guangfa Wang
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

7.  Clinical Impact of Compensatory Hyperinflation of the Nontreated Adjacent Lobe After Bronchoscopic Lung Volume Reduction with Valves.

Authors:  Johannes Wienker; Kaid Darwiche; Julia Wälscher; Jane Winantea; Michael Hagemann; Erik Büscher; Abhinav Singla; Christian Taube; Rüdiger Karpf-Wissel
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-07-01

8.  Revision Bronchoscopy After Endobronchial Valve Treatment for Emphysema: Indications, Findings and Outcomes.

Authors:  Sharyn A Roodenburg; Karin Klooster; Jorine E Hartman; T David Koster; Marlies van Dijk; Dirk-Jan Slebos
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-04-21

Review 9.  CT-Based Commercial Software Applications: Improving Patient Care Through Accurate COPD Subtyping.

Authors:  Jennifer M Wang; Sundaresh Ram; Wassim W Labaki; MeiLan K Han; Craig J Galbán
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-04-26

10.  Endobronchial coils for emphysema: Dual mechanism of action on lobar residual volume reduction.

Authors:  Jorine E Hartman; Pallav L Shah; Frank Sciurba; Felix J F Herth; Dirk-Jan Slebos
Journal:  Respirology       Date:  2020-04-08       Impact factor: 6.424

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.